128 related articles for article (PubMed ID: 29161363)
1. Improved survival in metastatic germ-cell cancer.
Fankhauser CD; Sander S; Roth L; Beyer J; Hermanns T
Ann Oncol; 2018 Feb; 29(2):347-351. PubMed ID: 29161363
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Factors and Treatment Results After Bleomycin, Etoposide, and Cisplatin in Germ Cell Cancer: A Population-based Study.
Kier MG; Lauritsen J; Mortensen MS; Bandak M; Andersen KK; Hansen MK; Agerbaek M; Holm NV; Dalton SO; Johansen C; Daugaard G
Eur Urol; 2017 Feb; 71(2):290-298. PubMed ID: 27649970
[TBL] [Abstract][Full Text] [Related]
3. Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors.
Albany C; Adra N; Snavely AC; Cary C; Masterson TA; Foster RS; Kesler K; Ulbright TM; Cheng L; Chovanec M; Taza F; Ku K; Brames MJ; Hanna NH; Einhorn LH
Ann Oncol; 2018 Feb; 29(2):341-346. PubMed ID: 29140422
[TBL] [Abstract][Full Text] [Related]
4. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor.
Kawai K; Hinotsu S; Oikawa T; Sekido N; Hattori K; Miyanaga N; Hasegawa Y; Kojima H; Shimazui T; Akaza H
Jpn J Clin Oncol; 2006 Nov; 36(11):723-30. PubMed ID: 17082218
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3).
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn-Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Oing C; Bokemeyer C
Urol Oncol; 2019 Nov; 37(11):809.e19-809.e25. PubMed ID: 31494007
[TBL] [Abstract][Full Text] [Related]
7. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database.
Lorch A; Bascoul-Mollevi C; Kramar A; Einhorn L; Necchi A; Massard C; De Giorgi U; Fléchon A; Margolin K; Lotz JP; Germà-Lluch JR; Powles T; Kollmannsberger C; Beyer J
J Clin Oncol; 2011 Jun; 29(16):2178-84. PubMed ID: 21444870
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
9. Improved outcomes in metastatic germ cell cancer: results from a large cohort study.
Hentrich M; Debole J; Jurinovic V; Gerl A
J Cancer Res Clin Oncol; 2021 Feb; 147(2):533-538. PubMed ID: 32772232
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics and Treatment Outcomes of Patients With Advanced Germ Cell Tumor Treated at a Tertiary Cancer Center in Brazil.
Vasconcellos VF; Bastos DA; Pereira AAL; Watarai GY; Pereira BR; de Godoy A; Almeida-Silva J; Muniz DQB; Guglielmetti GB; Nahas WC; Dzik C
J Glob Oncol; 2019 Feb; 5():1-8. PubMed ID: 30779600
[TBL] [Abstract][Full Text] [Related]
11. Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors.
Seidel C; Daugaard G; Tryakin A; Necchi A; Cohn Cedermark G; Ståhl O; Hentrich M; Brito M; Albany C; Taza F; Gerl A; Oechsle K; Bokemeyer C
Eur J Cancer; 2018 May; 94():16-25. PubMed ID: 29505967
[TBL] [Abstract][Full Text] [Related]
12. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
[TBL] [Abstract][Full Text] [Related]
13. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
14. Dose-dense chemotherapy for untreated poor-prognosis and relapsed germ-cell tumours: an 18-year experience with GAMEC chemotherapy.
Shamash J; Mee M; Sarker SJ; Wilson P; Ansell W; Greenwood M; Berney D; Alifrangis C
BJU Int; 2020 Jun; 125(6):843-852. PubMed ID: 31688976
[TBL] [Abstract][Full Text] [Related]
15. First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
Berger LA; Bokemeyer C; Lorch A; Hentrich M; Kopp HG; Gauler TC; Beyer J; de Wit M; Mayer F; Boehlke I; Oing C; Honecker F; Oechsle K
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1211-20. PubMed ID: 24696231
[TBL] [Abstract][Full Text] [Related]
16. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
17. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients.
Gonzalez-Billalabeitia E; Castellano D; Sobrevilla N; Guma J; Hervas D; Luengo MI; Aparicio J; Sanchez-Muñoz A; Mellado B; Saenz A; Valverde C; Fernandez A; Margeli M; Duran I; Fernandez S; Sastre J; Ros S; Maroto P; Manneh R; Cerezuela P; Carmona-Bayonas A; Ayala de la Peña F; Luis Aguilar J; Rivera S; García Del Muro X; Germà-Lluch JR;
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122896
[TBL] [Abstract][Full Text] [Related]
19. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
[TBL] [Abstract][Full Text] [Related]
20. [Result of treatment for advanced germ cell tumor in the last decade].
Ishioka J; Kageyama Y; Inoue M; Fukui N; Numao N; Saito K; Ichiyanagi N; Tanak M; Hyochi N; Fukuda H; Higashi Y
Nihon Hinyokika Gakkai Zasshi; 2010 Mar; 101(3):539-46. PubMed ID: 20387513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
